Recent news on Zenapax

Advair Not Likely To Be Displaced With Launch Of New Product  -  May 23, 2007
MediaPost Publications,Centocor/Schering-Plough/Tanabe/Janssen Pharmaceuticals' golimumab, Abbott/Eisai's Humira, and PDL BioPharma's Zenapax will generate $785 million in

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients ...  -  Apr 6, 2007
Drug Newswire (press release),Hoffman-La Roche, Inc. currently markets daclizumab under the name Zenapax(R) under a license from PDL. Zenapax antibody is indicated for the prophylaxis of

YM BioSciences Strengthens Program Management of Lead Drugs  -  Apr 5, 2007
Drug Newswire (press release),La-Roche Inc. with leadership responsibility through NDA filings and certain of the approvals for Xeloda(TM), Fortovase(TM), Zenapax(TM), Xenical(TM).

Interactive Agencies—Runner-up: OTOi  -  Apr 2, 2007
BtoB Magazine,OTOi created brand guidelines and Web sites for three of Roche's leading brands—CellCept, Valcyte and Zenapax—targeting physicians and patients.

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients ...  -  Mar 13, 2007
PipelineReview.com (press release),Hoffman-La Roche, Inc. currently markets daclizumab under the name Zenapax(R) under a license from PDL. Zenapax antibody is indicated for the prophylaxis of

PDL BioPharma drug does well in multiple sclerosis trial  -  Mar 13, 2007
Bizjournals.com,Hoffman-LaRoche Inc. sells daclizumab under the brand name Zenapax to treat organ rejection in kidney transplant patients. Hoffman-LaRoche sells it under a

Biogen, PDL say daclizumab trial meets main goal  -  Mar 13, 2007
Pharma Times (subscription),...transplant maintenance and the Swiss firm currently sells the drug under the name Zenapax for acute organ rejection in patients receiving renal transplants.

Biogen, PDL Drug Passes Clinical Trial  -  Mar 12, 2007
Forbes,The drug is already marketed by Hoffman-La Roche under a license from PDL as the kidney organ rejection treatment Zenapax. PDL shares rose 46 cents,

PDL treatment successful in Phase 2 trial  -  Mar 12, 2007
East Bay Business Times,It is marketed by Hoffman-La Roche Inc. under the name Zenapax, under license from PDL. The two companies said they will present the new study results at an

Biotech Day in Review: Schering-Plough Buys Organon for $14.4 Billion  -  Mar 13, 2007
Seeking Alpha,Roche (RHHBY) markets Zenapax as an anti-rejection drug for organ transplant patients. Biogen Idec gained 79 cents to end at $44.09, and PDL climbed 43

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Yahoo! News (press release)...which consisted of $15.8 million related to the write-off of the Company's option to re-acquire rights to manufacture and market Zenapax for acute renal

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional